NR4A1 and breast cancer: Hormone receptor-positive Breast Cancer (BC) driven by PI3K/Akt/mTOR signaling remains a major therapeutic challenge, particularly in settings where conventional chemotherapy causes severe systemic and reproductive toxicity.